negative control

The PKR Inhibitor, negative control, is an inactive structural analog of RNA-dependent protein kinase (PKR) inhibitors, serving as a negative control. Additionally, it can inhibit LK-induced neuronal death, demonstrating significant neuroprotective properties.

saRNA negative control is a type of saRNA that can be used as a negative control.

Volanesorsenscramble negative control is the negative control form of Volanesorsen with the sequence: CAUGUTCUTCUGCATGUCAU. Volanesorsen (ISIS 304801) is an antisense oligonucleotide inhibitor targeting apolipoprotein CIII (apo-CIII) mRNA, effectively reducing triglyceride levels and improving insulin resistance.

GalNac-siRNA negative control (21nt) serves as the negative control form of GalNac-siRNA. GalNac-siRNA is an inhibitor conjugate targeting the asialoglycoprotein receptor (ASGPR). This compound holds potential for research into hereditary transthyretin amyloidosis, acute hepatic porphyria, hemophilia, and hypercholesterolemia.

Cy5-MicroRNA Mimic Negative Control is a Cy5-labeled MicroRNA Mimic Negative Control. This compound is a 21-nucleotide miRNA mimic used as a negative control. The sequence of the MicroRNA Mimic Negative Control is designed based on the cel-mir-239b sequence, which is widely utilized as a negative control. It exhibits minimal sequence homology with human, mouse, and rat miRNA.

siRNA negative control (In Vivo) is an siRNA designed to serve as a negative control. It is modified with cholesterol and methoxy groups, making it suitable as a negative control in animal studies.

Elebsiran scramble negative control is a scrambled sequence variant of Elebsiran, utilizing the same modification method. This compound serves as a negative control for Elebsiran.

Emapticap pegol scramble negative control, an oligonucleotide aptamer, serves as the negative control for Emapticap pegol.

ELA-14 negative control is an inactive peptide that serves as a negative control for ELA-14.

ARCC 4 negative control is a negative control for ARCC 4. Binds androgen receptors (AR) without inducing degradation.

The compound is a negative control peptide for the Bax inhibitor peptides V5 and P5.

JNK-IN-15, Cell-Permeable, Negative Control serves as the negative control for JNK-IN-15, Cell-Permeable. JNK-IN-15, Cell-Permeable functions as an inhibitor of JNK.

Acetyl-Calpastatin(184-210)(human), Negative Control is a control scrambled peptide corresponding to Acetyl-Calpastatin(184-210)(human). Acetyl-Calpastatin(184-210)(human) functions as a potent, selective, and reversible calpain inhibitor.

MG-132 negative control serves as the negative control for MG-132. MG-132 is a potent and reversible inhibitor of the proteasome (proteasome).

Microtubule destabilizing agent-3, negative control, is an analog of B32B3 and serves as the negative control for Microtubule destabilizing agent-3. This agent functions as a microtubule destabilizer by disrupting microtubule stability, which promotes mitotic arrest and exhibits an anti-myeloma phenotype, ultimately leading to cell death. It can also induce G2/M phase arrest and caspase-dependent apoptosis.

ERK Inhibitor II (Negative control) effectively blocks extracellular signal-regulated kinase (ERK) activity and interferes with insulin receptor activation, serving as a valuable tool in diabetes research.

SP 600125, negative control is a methylated analog of SP 600125 and can be used as a negative control for SP 600125. SP 600125, negative control inhibits DTP3 and GADD45β/MKK7 (growth arrest and DNA damage-inducible β/mediator-activated protein kinase kinase kinase 7) and is capable of restoring activation.The IC50s of SP 600125, negative control against JNK2 and JNK3 were 18 and 24 μM, respectively.

SiRNA Negative Control is an siRNA sequence that does not target any gene product and is a negative control for siRNA.

(S)-BAY-293 is a potent pan-KRAS inhibitor used in the study of primary non-small cell lung and pancreatic cancers.

GL-V9 is an AMPK activator, protecting against colitis-associated colorectal cancer by limiting NLRP3 inflammasome through autophagy.

ELA RR>GG (ELA-32 negative control) is a mutant peptide of ELABELA, serving as a negative control for ELABELA.

BRD3067 serves as a negative control for Tubacin A (AGCR-13900, TubA, AG-CR13900). BRD3067 is a derivative of Tubacin and functions as a selective inhibitor of histone deacetylase 6 (HDAC6), exhibiting an IC50 value of 15 nM in cell-free assays. BRD3067 has demonstrated potential anticancer and anti-inflammatory activities, making it a valuable tool for studying HDAC6 inhibition.

BRD4097, a negative control in the HDAC1/2/3/8 assay, is a selective histone deacetylase (HDAC3) inhibitor that can be used to protect b-cells and improve insulin resistance, help promote cognitive function and enhance learning and memory formation.

MS 154N is a negative control for MS 154. The compound exhibits high binding-affinity for WT and L858R-mutant EGFR (Kdvalues are 3 and 4.3 nM, respectively), but does not significantly induce degradation of EGFR mutants.